{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T22:25:09Z","timestamp":1768170309587,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jcyt.2025.09.012","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:59:35Z","timestamp":1759341575000},"page":"101989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unrelated donor transplantation offers a real curative opportunity for patients with transfusion-dependent thalassaemia. A multicenter retrospective study on behalf of the Spanish group for hematopoietic transplantation and cellular therapy (GETH-TC)"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5366-8384","authenticated-orcid":false,"given":"Mar\u00eda Isabel","family":"Ben\u00edtez-Carabante","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Men\u00e1rguez","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Luz Ur\u00eda","family":"Oficialdegui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6019-6557","authenticated-orcid":false,"given":"Cristina Bel\u00e9ndez","family":"Bieler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa Panesso","family":"Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1610-4790","authenticated-orcid":false,"given":"Mercedes Plaza","family":"Fornieles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Vinagre","family":"Enr\u00edquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graciela G\u00f3mez","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8134-9682","authenticated-orcid":false,"given":"M\u00f3nica L\u00f3pez","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda P\u00e9rez","family":"Hurtado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-1056","authenticated-orcid":false,"given":"Montserrat","family":"Torrent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Alonso","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8086-296X","authenticated-orcid":false,"given":"Cristina","family":"Diaz-de-Heredia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jcyt.2025.09.012_bib0001","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clinthera.2019.12.003","article-title":"Systematic literature review of the burden of disease and treatment for transfusion-dependent \u03b2-thalassemia","volume":"42","author":"Betts","year":"2020","journal-title":"Clin Ther"},{"issue":"45","key":"10.1016\/j.jcyt.2025.09.012_bib0002","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027522","article-title":"Molecular genetics of \u03b2-thalassemia: a narrative review","volume":"100","author":"Jaing","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jcyt.2025.09.012_bib0003","unstructured":"Porter D, Taher J. 4 TH EDITION (Version 2.0) SSAEMIA INTERNATIONAL FEDERATION."},{"issue":"5","key":"10.1016\/j.jcyt.2025.09.012_bib0004","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s00277-024-05694-z","article-title":"Spanish registry of hemoglobinopathies and rare anemias (REHem-AR): demographics, complications, and management of patients with \u03b2-thalassemia","volume":"103","author":"Bard\u00f3n-Cancho","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2025.09.012_bib0005","doi-asserted-by":"crossref","unstructured":"Taher AT, Musallam KM, Cappellini MD. \u03b2-Thalassemias. Longo DL, editor. N Engl J Med [Internet]. 2021 ;384(8):727-43. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33626255\/","DOI":"10.1056\/NEJMra2021838"},{"issue":"2","key":"10.1016\/j.jcyt.2025.09.012_bib0006","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMct1004810","article-title":"Iron-chelating therapy for transfusional iron overload","volume":"364","author":"Brittenham","year":"2011","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jcyt.2025.09.012_bib0007","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood-2018-06-818187","article-title":"How I manage medical complications of \u03b2-thalassemia in adults","volume":"132","author":"Taher","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jcyt.2025.09.012_bib0008","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000732","article-title":"2021 thalassaemia international federation guidelines for the management of transfusion-dependent thalassemia","volume":"6","author":"Farmakis","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.jcyt.2025.09.012_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100588","article-title":"Challenges of blood transfusions in \u03b2-thalassemia","volume":"37","author":"Shah","year":"2019","journal-title":"Blood Rev"},{"issue":"13","key":"10.1016\/j.jcyt.2025.09.012_bib0010","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","article-title":"A phase 3 trial of luspatercept in patients with transfusion-dependent \u03b2-thalassemia","volume":"382","author":"Cappellini","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jcyt.2025.09.012_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2022.100790","article-title":"Right in time: Mitapivat for the treatment of anemia in \u03b1- and \u03b2-thalassemia","volume":"3","author":"Musallam","year":"2022","journal-title":"Cell reports Med"},{"issue":"1","key":"10.1016\/j.jcyt.2025.09.012_bib0012","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/hematology.2023000468","article-title":"Pyruvate kinase activators: targeting red cell metabolism in thalassemia","volume":"2023","author":"Kuo","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2025.09.012_bib0013","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1182\/blood-2021-145752","article-title":"Trial in progress: a phase 2, open-label study evaluating the safety and efficacy of the PKR activator etavopivat (FT-4202) in patients with thalassemia or sickle cell disease","volume":"138","author":"Lal","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jcyt.2025.09.012_bib0014","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2013.099747","article-title":"Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: Indications and management recommendations from an international expert panel","volume":"99","author":"Angelucci","year":"2014","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.jcyt.2025.09.012_bib0015","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood-2013-03-489112","article-title":"Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling","volume":"122","author":"Locatelli","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.09.012_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2015.09.012","article-title":"On modeling human leukocyte antigen-identical sibling match probability for allogeneic hematopoietic cell transplantation: estimating the need for an unrelated donor source","author":"Besse","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jcyt.2025.09.012_bib0017","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/bmt.2015.293","article-title":"Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010","volume":"51","author":"Baronciani","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jcyt.2025.09.012_bib0018","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2141.2008.07385.x","article-title":"Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major","volume":"143","author":"Bernardo","year":"2008","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jcyt.2025.09.012_bib0019","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00277-021-04732-4","article-title":"Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major","volume":"101","author":"L\u00fcftinger","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2025.09.012_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2011.01.012","article-title":"Umbilical cord blood transplantation for children with thalassemia and sickle cell disease","author":"Ruggeri","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jcyt.2025.09.012_bib0021","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/bmt.2011.39","article-title":"Unrelated cord blood transplantation for thalassaemia: a single-institution experience of 35 patients","volume":"47","author":"Jaing","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jcyt.2025.09.012_bib0022","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1182\/bloodadvances.2017012005","article-title":"Haploidentical HSCT for hemoglobinopathies: improved outcomes with TCR\u03b1\u03b2+\/CD19+-depleted grafts","volume":"2","author":"Gaziev","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jcyt.2025.09.012_bib0023","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa2113206","article-title":"Betibeglogene Autotemcel Gene Therapy for Non-\u03b20\/\u03b20 Genotype \u03b2-Thalassemia","volume":"386","author":"Locatelli","year":"2022","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jcyt.2025.09.012_bib0024","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","article-title":"Exagamglogene Autotemcel for Transfusion-Dependent \u03b2-Thalassemia","volume":"390","author":"Locatelli","year":"2024","journal-title":"N Engl J Med"},{"issue":"10468","key":"10.1016\/j.jcyt.2025.09.012_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(24)01884-1","article-title":"Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype \u03b2-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial","volume":"404","author":"Kwiatkowski","year":"2024","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.jcyt.2025.09.012_bib0026","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41409-024-02251-0","article-title":"Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT","volume":"59","author":"Sureda","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jcyt.2025.09.012_bib0027","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.bbmt.2017.08.038","article-title":"Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease","volume":"23","author":"Abraham","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jcyt.2025.09.012_bib0028","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount Sinai acute GVHD international consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jcyt.2025.09.012_bib0029","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jcyt.2025.09.012_bib0030","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.ymthe.2024.03.005","article-title":"Autologous gene therapy for hemoglobinopathies: from bench to patient\u2019s bedside","volume":"32","author":"Locatelli","year":"2024","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.jcyt.2025.09.012_bib0031","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2012-04-423822","article-title":"Allogeneic hematopoietic stem cell transplantation in thalassemia major: Results of a reduced-toxicity conditioning regimen based on the use of treosulfan","volume":"120","author":"Bernardo","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jcyt.2025.09.012_bib0032","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bbmt.2007.12.491","article-title":"Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major","volume":"14","author":"Ghavamzadeh","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jcyt.2025.09.012_bib0033","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/j.bbmt.2019.05.005","article-title":"Gonadal function after busulfan compared with treosulfan in children and adolescents undergoing allogeneic hematopoietic stem cell transplant","volume":"25","author":"Faraci","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jcyt.2025.09.012_bib0034","doi-asserted-by":"crossref","first-page":"529.e1","DOI":"10.1016\/j.jtct.2023.05.003","article-title":"Effect of busulfan and treosulfan on gonadal function after allogeneic stem cell transplantation in children and adolescents with nonmalignant diseases is not exposure-dependent","volume":"29","author":"van der Stoep","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"17","key":"10.1016\/j.jcyt.2025.09.012_bib0035","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jcyt.2025.09.012_bib0036","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/TP.0000000000003327","article-title":"Graft-versus-host disease prophylaxis with abatacept reduces severe acute graft-versus-host disease in allogeneic hematopoietic stem cell transplant for beta-thalassemia major with busulfan, fludarabine, and thiotepa","volume":"105","author":"Khandelwal","year":"2021","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.jcyt.2025.09.012_bib0037","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/INF.0000000000004208","article-title":"Pharmacokinetics, safety, and efficacy of letermovir for cytomegalovirus prophylaxis in adolescent hematopoietic cell transplantation recipients","volume":"43","author":"Groll","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jcyt.2025.09.012_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.05.021","article-title":"Letermovir primary and secondary prophylaxis in pediatric recipients of allogeneic haematopoietic stem cell transplant","author":"Vendemini","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jcyt.2025.09.012_bib0039","doi-asserted-by":"crossref","DOI":"10.3390\/cells8010047","article-title":"Adoptive T cell therapy strategies for viral infections in patients receiving haematopoietic stem cell transplantation","volume":"8","author":"Ottaviano","year":"2019","journal-title":"Cells"},{"issue":"16","key":"10.1016\/j.jcyt.2025.09.012_bib0040","first-page":"3894","article-title":"Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease","volume":"4","author":"Ngwube","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2025.09.012_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.06.015","article-title":"Impact of abatacept inclusive graft versus host disease prophylaxis in pediatric stem cell transplantation for hemoglobinopathy","author":"Shah","year":"2025","journal-title":"Transplant Cell Ther"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925008497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925008497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:50:20Z","timestamp":1767963020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925008497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1465324925008497"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.09.012","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unrelated donor transplantation offers a real curative opportunity for patients with transfusion-dependent thalassaemia. A multicenter retrospective study on behalf of the Spanish group for hematopoietic transplantation and cellular therapy (GETH-TC)","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101989"}}